4.22
price down icon0.47%   -0.02
after-market Handel nachbörslich: 4.15 -0.07 -1.66%
loading
Schlusskurs vom Vortag:
$4.24
Offen:
$4.24
24-Stunden-Volumen:
356.80K
Relative Volume:
0.31
Marktkapitalisierung:
$151.86M
Einnahmen:
$317.00K
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-2.2328
EPS:
-1.89
Netto-Cashflow:
$-49.31M
1W Leistung:
+0.96%
1M Leistung:
+64.84%
6M Leistung:
+100.00%
1J Leistung:
+251.67%
1-Tages-Spanne:
Value
$3.95
$4.24
1-Wochen-Bereich:
Value
$3.82
$4.35
52-Wochen-Spanne:
Value
$1.00
$4.60

Immuneering Corp Stock (IMRX) Company Profile

Name
Firmenname
Immuneering Corp
Name
Telefon
617-500-8080
Name
Adresse
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Name
Mitarbeiter
54
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-19
Name
Neueste SEC-Einreichungen
Name
IMRX's Discussions on Twitter

Vergleichen Sie IMRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMRX
Immuneering Corp
4.22 150.42M 317.00K -53.47M -49.31M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Immuneering Corp Stock (IMRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-13 Herabstufung Morgan Stanley Equal-Weight → Underweight
2024-03-15 Herabstufung Jefferies Buy → Hold
2024-03-15 Bestätigt Needham Buy
2024-03-15 Herabstufung TD Cowen Outperform → Market Perform
2023-12-01 Eingeleitet Needham Buy
2023-06-26 Fortgesetzt Oppenheimer Outperform
2023-04-19 Hochstufung Mizuho Neutral → Buy
2023-04-19 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-03-30 Eingeleitet Mizuho Neutral
2023-02-03 Herabstufung Morgan Stanley Equal-Weight → Underweight
2022-07-08 Eingeleitet Chardan Capital Markets Buy
2022-04-01 Eingeleitet Oppenheimer Outperform
2022-01-07 Eingeleitet Piper Sandler Overweight
Alle ansehen

Immuneering Corp Aktie (IMRX) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about Immuneering Corporation stockFree Stock Market Return Analysis - Autocar Professional

Jul 22, 2025
pulisher
Jul 19, 2025

What drives Immuneering Corporation stock priceFastest-growing stock picks - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25 - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

Is Immuneering Corporation a good long term investmentSuperior stock growth - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Immuneering Corporation stock price move sharplyTop Gaining Low Risk Assets - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow

Jul 10, 2025
pulisher
Jul 09, 2025

Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan

Jul 09, 2025
pulisher
Jul 07, 2025

Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com

Jul 07, 2025
pulisher
Jul 01, 2025

Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus

Jul 01, 2025
pulisher
Jun 27, 2025

Immuneering (IMRX) Soars 10.66% on Positive Trial Data, Insider Buying - AInvest

Jun 27, 2025
pulisher
Jun 26, 2025

At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - Stocksregister

Jun 26, 2025
pulisher
Jun 25, 2025

Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data - Investing.com

Jun 25, 2025
pulisher
Jun 24, 2025

Immuneering (IMRX) CBO Brakewood buys $4804 in shares - Investing.com

Jun 24, 2025
pulisher
Jun 23, 2025

Immuneering (IMRX) director Feinberg buys $63k in shares - Investing.com

Jun 23, 2025
pulisher
Jun 20, 2025

Immuneering (IMRX) CEO Zeskind buys $50k+ in shares - Investing.com

Jun 20, 2025
pulisher
Jun 19, 2025

Immuneering (NASDAQ:IMRX) Receives Buy Rating from Needham & Company LLC - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com

Jun 18, 2025
pulisher
Jun 17, 2025

Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering stock rises after positive pancreatic cancer trial data - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering Stock Soars 25.74% on Promising Cancer Trial Results - AInvest

Jun 17, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World

Jun 12, 2025
pulisher
Jun 06, 2025

Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus

Jun 05, 2025
pulisher
May 29, 2025

Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Immuneering Corporation to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq

May 29, 2025
pulisher
May 15, 2025

‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail

May 15, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World

May 07, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks

May 07, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks

May 06, 2025

Finanzdaten der Immuneering Corp-Aktie (IMRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):